AZIYO BIOLOGICS(AZYO) - 2025 Q4 - Annual Report

Financial Performance - Elutia divested its cardiac implantable electronic device (CIED) product family for an aggregate purchase price of up to $88.0 million in cash, with $80.4 million received at closing[26]. - The sale of the CIED business resulted in a net gain of $76.1 million for Elutia in 2025[32]. - The company reported losses from continuing operations of $26.9 million and $30.7 million for the years ended December 31, 2025, and 2024, respectively, and expects losses to continue for the foreseeable future[139]. - The company completed the sale of its cardiac implantable electronic device (CIED) business on October 1, 2025, which may impact future financial contributions[135]. - The sale of the Orthobiologics Business generated approximately $14.6 million, with potential additional earn-out payments of up to $20.0 million[34]. - The sale of the Orthobiologics Business to Berkeley on November 8, 2023, resulted in an initial payment of $14.6 million, with potential additional earn-out payments of up to $20.0 million based on future revenues[166]. - Future capital needs are uncertain, and the company may need to raise additional funds through equity offerings or debt financings, which could dilute existing shareholders[150]. Market Opportunities - The U.S. market opportunity for Elutia's next-generation antibiotic-eluting biomatrix products is estimated to be approximately $1.5 billion[42]. - The estimated U.S. market opportunity for biologic matrices is approximately $1.5 billion, accounting for over 60% of reconstruction spending[75]. - EluPro, the first antibiotic-eluting biologic matrix envelope, achieved annualized revenues of approximately $19 million, with EluPro contributing about $14 million[41]. Product Development - Elutia's lead development programs include NXT-41 and NXT-41x, aimed at addressing complications in reconstructive procedures, with a focus on local antibiotic drug delivery[28]. - The NXT-41 and NXT-41x development programs are expected to receive FDA clearance in the second half of 2026 and mid-2027, respectively[77]. - The company is focusing on the development of NXT-41x, a biomatrix aimed at improving interactions between implanted medical devices and patients, which will require significant investments[136]. Regulatory Environment - The company’s products are subject to extensive regulation by the FDA and other authorities, ensuring safety and effectiveness for intended uses[89]. - Medical devices are classified into three categories based on risk, with Class I devices being low-risk and usually exempt from premarket notification, while Class III devices require more rigorous PMA approval[90]. - The 510(k) clearance process typically takes three to twelve months, but may extend longer if additional information is required by the FDA[93]. - Significant modifications to a device after 510(k) clearance necessitate a new clearance or PMA approval, with non-compliance potentially leading to regulatory fines[94]. - The PMA process requires extensive pre-clinical and clinical data, with FDA having 180 days for review, often extending beyond this period[95]. - Clinical studies must adhere to FDA's IDE regulations, requiring approval from an Institutional Review Board (IRB) at each site[98]. - Post-market regulations include mandatory reporting of device-related incidents and compliance with quality management system requirements[101]. Competitive Landscape - SimpliDerm competes against products like AbbVie's AlloDerm and various synthetic mesh products in the soft tissue repair market[63]. - The company faces significant competition from established firms with greater resources, which could hinder market penetration and operating results[185]. - Pricing pressure from cost-containment efforts by customers and third-party payors could adversely affect sales and profitability[189]. - The healthcare industry is experiencing consolidation trends, which may exert downward pressure on product prices and affect sales volumes[193]. Legal and Liability Risks - The company has recorded a total estimated contingent liability of $11.2 million related to lawsuits from the FiberCel and Viable Bone Matrix recalls, with $6.8 million for FiberCel and $4.4 million for VBM as of December 31, 2025[141]. - As of December 31, 2025, the company has no insurance coverage for the FiberCel recall liability, which poses a significant financial risk[142]. - The company faces ongoing litigation related to the FiberCel and VBM recalls, with 110 separate lawsuits or claims received since September 2021[143]. - Warranty claims and product recalls could result in significant costs and negatively affect the company's financial condition[207][212]. - The company may face significant legal costs and liabilities due to product liability claims, which could adversely affect its cash flow and financial position[149]. Operational Challenges - The company relies on a limited number of suppliers, including a single supplier for SIS ECM biomaterial, which poses risks of significant product development costs and delivery delays[168]. - The company relies on independent sales agents for generating Women's Health and Cardiovascular sales, which poses risks related to customer relationships and sales performance[173]. - The company must manage growth effectively to penetrate and service existing and future markets, which may strain operational and financial resources[184]. - Shipping performance issues, including delays and increased rates, could adversely affect the company's operating margins and results[194]. - Increased prices for raw materials and supplies could negatively impact the company's profitability and financial condition[196][197]. - The company may struggle to pass on cost increases to customers, potentially leading to lower margins and profitability[198]. - Inaccurate demand forecasting and inventory management could result in lost sales and decreased margins, adversely affecting financial results[199]. - The company faces risks of inventory obsolescence due to the shelf life of products, which could lead to material adverse effects on profitability[200]. Human Resources and Workplace Culture - The company is committed to fostering an equitable and inclusive workplace, which is essential for attracting and retaining qualified personnel[128]. - The company aims to offer competitive pay and benefits to attract and retain exceptional talent, including an annual cash incentive program and long-term equity incentive plans[129]. - The company may experience challenges in attracting and retaining skilled personnel due to intense competition in the healthcare industry[224]. - Retaining key management personnel is essential for navigating business challenges and achieving growth objectives[224]. Cybersecurity Risks - Company faces increasing risks from cyberattacks, with sophisticated groups targeting sensitive data and IT systems[218]. - Potential financial impacts from unauthorized access or data breaches could lead to legal claims and damage to reputation[221]. - Cybersecurity insurance may not cover all claims, which could adversely affect financial condition if large claims arise[223]. - The evolving nature of cyber threats complicates prevention and detection efforts, increasing operational risks[218].